Diethylcarbamazine
Diethylcarbamazine is a medication used in the treatment of filariasis including lymphatic filariasis, tropical pulmonary eosinophilia, and loiasis. It may also be used for prevention of loiasis in those at high risk. While it has been used for onchocerciasis (river blindness), ivermectin is preferred. It is taken by mouth.
Clinical data | |
---|---|
Other names | DEC, N, N-diethyl-4-methyl-1-piperazine carboxamide |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.001.840 |
Chemical and physical data | |
Formula | C10H21N3O |
Molar mass | 199.298 g·mol−1 |
3D model (JSmol) | |
Melting point | 47 to 49 °C (117 to 120 °F) |
SMILES
| |
| |
(verify) |
Common side effects include itching, facial swelling, headaches, and feeling tired. Other side effects include vision loss and dizziness. It is a recommended treatment in pregnancy and appears to be safe for the baby. The World Health Organization; however, recommends waiting until after pregnancy for treatment when feasible. It is made from 4-methyl-piperazine.
Diethylcarbamazine was discovered in 1947 by Yellapragada Subbarow. It is on the World Health Organization's List of Essential Medicines. It is not commercially available in the United States but can be acquired from the Centers for Disease Control and Prevention.